摘要
阿达木抗体是一种特异性靶向人肿瘤坏死因子TNF-α的全人源单克隆抗体类药物.近年来先后被美国和欧盟批准用于类风湿关节炎、克罗恩病和银屑病关节炎等8种自身免疫性疾病的治疗.自2010年阿达木单抗在中国上市,已获批类风湿关节炎和强制性脊柱炎2种适应症的应用.因阿达木单抗疗效好,副作用小,其在临床上受到越来越多的关注.本文就阿达木单抗在中国的发展现状和研究成果进行扼要论述,以期为后续阿达木单抗在中国更为有效和广泛的临床应用提供帮助.
Human monoclonal antibody Adalimumab is an autoimmune drug with binding affinity towards tumor necrosis factor-α（TNF-α）.Adalimumab can therefore inhibit TNF-αbinding of TNF-αreceptor,to reduce inflammatory response.Adalimumab has been approved by both SFDA（the United States Food Drug Administration）and EMA（European Medicines Agency）for eight indications of autoimmune diseases including rheumatoid arthritis,Crohn’s disease and psoriatic arthritis.CFDA（China Food Drug Administration）has also approved Adalimumab for two indications：rheumatoid arthritis and ankylosing spondylitis.This review discusses the clinical development and recent research of Adalimumab in China,to explore wider clinical applications of Adalimumab in China.
出处
《北京师范大学学报（自然科学版）》
CAS
CSCD
北大核心
2015年第6期591-594,共4页
Journal of Beijing Normal University(Natural Science)
基金
高等学校博士学科点专项科研基金资助项目(20120003120025)
中央高校基本科研业务费专项资金资助项目(2013NT31)
国家自然科学基金资助项目(81301701)
